Literature DB >> 10190280

Regulation of cell adhesion by PAI-1.

D J Loskutoff1, S A Curriden, G Hu, G Deng.   

Abstract

Type I plasminogen activator inhibitor (PAI-1) is the primary inhibitor of tissue- and urokinase-type plasminogen activators. It circulates in plasma complexed with vitronectin (VN), the primary PAI-1 binding protein. The somatomedin B (SMB) domain of VN contains both the high affinity PAI-1 binding site and the specific site for urokinase plasminogen activator receptor (uPAR). PAI-1 is able to regulate uPAR-mediated cell adhesion by competing with uPAR for VN binding. Binding of PAI-1 to SMD may also affect integrin-mediated cell adhesion to VN by hindering integrin binding to the RGD sequence adjacent to the uPAR binding site.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10190280     DOI： 10.1111/j.1699-0463.1999.tb01526.x

Source DB:  PubMed          Journal:  APMIS        ISSN： 0903-4641            Impact factor:   3.205


  24 in total

Review 1.  The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.

Authors:  A Luttun; M Dewerchin; D Collen; P Carmeliet
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

2.  Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1.

Authors:  Rik Gijsbers; Hugo Ceulemans; Mathieu Bollen
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

3.  Directional migration and transcriptional analysis of oligodendrocyte precursors subjected to stimulation of electrical signal.

Authors:  Yongchao Li; Xinkun Wang; Li Yao
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-12       Impact factor: 4.249

4.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

Review 5.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

6.  The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice.

Authors:  Anthony J Courey; Jeffrey C Horowitz; Kevin K Kim; Timothy J Koh; Margaret L Novak; Natalya Subbotina; Mark Warnock; Bing Xue; Andrew K Cunningham; Yujing Lin; Monica P Goldklang; Richard H Simon; Daniel A Lawrence; Thomas H Sisson
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

7.  A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation.

Authors:  S Selvarajan; L R Lund; T Takeuchi; C S Craik; Z Werb
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

Review 8.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

Review 9.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

10.  The multiplex bead array approach to identifying serum biomarkers associated with breast cancer.

Authors:  Byoung Kwon Kim; Jong Won Lee; Pil Je Park; Yong Sung Shin; Won Young Lee; Kyung Ae Lee; Sena Ye; Heesun Hyun; Kyung Nam Kang; Donghwa Yeo; Youngdai Kim; Sung Yup Ohn; Dong Young Noh; Chul Woo Kim
Journal:  Breast Cancer Res       Date:  2009-04-28       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.